1-20 of 32
Naveen Garg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Free
Mahesh Swaminathan, Philip Thompson, Jan Burger, Musa Yilmaz, Nitin Jain, Tapan Kadia, Lucia Masarova, Yesid Alvarado Valero, Prithviraj Bose, Alessandra Ferrajoli, Ghayas Issa, Steven Kornblau, Farhad Ravandi, Koji Sasaki, Gautam Borthakur, Kelly Chien, Courtney DiNardo, Danielle Hammond, Elias Jabbour, Guillermo Montalban-Bravo, Naveen Pemmaraju, Nicholas Short, Koichi Takahashi, Wei Qiao, Xun Xu, Naveen Garg, Michael Keating, William Wierda
Journal: Blood
Blood (2025) 146 (Supplement 1): 681.
https://doi.org/10.1182/blood-2025-681
Published: 2025
Journal Articles

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Free
Nitin Jain, Alessandra Ferrajoli, Mahesh Swaminathan, Jan Burger, Vanthana Bharathi, Wei-Ying Jen, Himachandana Atluri, Alex Bataller, Elias Jabbour, Tapan Kadia, Gautam Borthakur, Koichi Takahashi, Kelly Chien, Musa Yilmaz, Naveen Pemmaraju, Naval Daver, Fadi Haddad, Yesid Alvarado Valero, Jo Ishizawa, Guillermo Montalban-Bravo, Cameron Noorbakhsh, Dhruv Kumar, Naveen Garg, Hyunsoo Hwang, Wei Qiao, Cameron Garcia, Anna Evangelio, Ana Ayala, Guillermo Garcia-Manero, Deepa Sampath, Varsha Gandhi, Michael Keating, Hagop Kantarjian, William Wierda
Journal: Blood
Blood (2025) 146 (Supplement 1): 680.
https://doi.org/10.1182/blood-2025-680
Published: 2025
Journal Articles

Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk Mantle Cell Lymphoma: The window-3 clinical trial

Free
Preetesh Jain, Sairah Ahmed, Chi Young Ok, Ranjit Nair, Ahmed Fetooh, Holly Hill, Tatiana Vasilyeva, Ajlan Al Zaki, Anastasiya Evdokimova, Viktor Smirnov, Tolina Turova, Ilya Anosov, Lizzie Sheehan, Selvi Thirumurthi, Anita Deswal, Cezar Iliescu, Vinh Nguyen, Joel Thomas, Naveen Garg, Dhruv Kumar, Cameron Noorbakhsh, Sa Wang, Keyur Patel, Francisco Vega, L. Jeffrey Medeiros, Guilin Tang, Partow Kebriaei, Neeraj Saini, Susan Wu, Bouthaina Dabaja, Nikkita Kotlov, Michael Goldberg, Cara Haymaker, Christopher Flowers, Sattva Neelapu, Michael Wang
Journal: Blood
Blood (2025) 146 (Supplement 1): 666.
https://doi.org/10.1182/blood-2025-666
Published: 2025
Journal Articles

Pirtobrutinib, venetoclax, and obinutuzumab for patients with richter transformation: A phase 2 trial

Free
Nitin Jain, Niranjan Khaire, Mahesh Swaminathan, Alessandra Ferrajoli, Jan Burger, Vishruth Shah, Kelly Chien, Gautam Borthakur, Koichi Takahashi, Naveen Pemmaraju, Prithviraj Bose, Jo Ishizawa, Beenu Thakral, Naveen Garg, Hyunsoo Hwang, Wei Qiao, Cameron Garcia, Anna Evangelio, Ana Ayala, Guillermo Garcia-Manero, Deepa Sampath, Varsha Gandhi, Michael Keating, Hagop Kantarjian, William Wierda
Journal: Blood
Blood (2025) 146 (Supplement 1): 89.
https://doi.org/10.1182/blood-2025-89
Published: 2025
Journal Articles

Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials

Free
Mahesh Swaminathan, Nitin Jain, Alexandra Lovell, Ashley Dinh, Alessandra Ferrajoli, Jan Burger, Musa Yilmaz, Tapan Kadia, Lucia Masarova, Yesid Alvarado Valero, Prithviraj Bose, Farhad Ravandi, Koji Sasaki, Wei Qiao, Zhouxuan Li, Naveen Garg, Michael Keating, William Wierda
Journal: Blood
Blood (2025) 146 (Supplement 1): 5687.
https://doi.org/10.1182/blood-2025-5687
Published: 2025
Journal Articles

Utility of PET/CT Imaging in Predicting Outcomes of Patients with Lymphoid Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Analysis from a Single Tertiary Center

Free
Rishab Prakash, James Long, Benjamin Mescher, Paul Edelkamp, Jr., Mark Knafl, Jeff Jin, Trey Kell, Naveen Garg, Ajlan Al Zaki, Dai Chihara, Luis Malpica, Ranjit Nair, Swaminathan P Iyer
Journal: Blood
Blood (2024) 144 (Supplement 1): 5127.
https://doi.org/10.1182/blood-2024-211892
Published: 2024
Journal Articles

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Free
Mahesh Swaminathan, Philip A. Thompson, Jan A. Burger, Musa Yilmaz, Nitin Jain, Tapan M. Kadia, Lucia Masarova, Yesid Alvarado Valero, Prithviraj Bose, Alessandra Ferrajoli, Ghayas C. Issa, Steven M. Kornblau, Farhad Ravandi, Koji Sasaki, Gautam Borthakur, Kelly S. Chien, Courtney D. DiNardo, Danielle Hammond, Elias Jabbour, Guillermo Montalban-Bravo, Naveen Pemmaraju, Nicholas J. Short, Koichi Takahashi, Francesco Paolo Tambaro, Wei Qiao, Naveen Garg, Michael J. Keating, William G. Wierda
Journal: Blood
Blood (2024) 144 (Supplement 1): 1855.
https://doi.org/10.1182/blood-2024-211110
Published: 2024
Journal Articles

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Free
Nitin Jain, Alessandra Ferrajoli, Mahesh Swaminathan, Patrick K. Reville, Jan A. Burger, Vanthana Bharathi, Himachandana Atluri, Hua-Jay J Cherng, Alex Bataller, Elias Jabbour, Tapan M. Kadia, Gautam Borthakur, Koichi Takahashi, Kelly S. Chien, Musa Yilmaz, Naveen Pemmaraju, Naval Daver, Fadi G. Haddad, Yesid Alvarado Valero, Jo Ishizawa, Guillermo Montalban-Bravo, Naveen Garg, Hyunsoo Hwang, Wei Qiao, Cameron Garcia, Anna Evangelio, Ana Ayala, Deepa Sampath, Varsha Gandhi, Michael J. Keating, Hagop M. Kantarjian, William G. Wierda
Journal: Blood
Blood (2024) 144 (Supplement 1): 1011.
https://doi.org/10.1182/blood-2024-211454
Published: 2024
Journal Articles

Atezolizumab Combined with Venetoclax and Obinutuzumab for Frontline CLL

Free
Patrick K. Reville, Sogand Sajedi, Alessandra Ferrajoli, Jan A. Burger, Michael J. Keating, Naveen Garg, Qing Deng, Michael R. Green, Hussein A. Abbas, William G. Wierda, Nitin Jain
Journal: Blood
Blood (2024) 144 (Supplement 1): 1014.
https://doi.org/10.1182/blood-2024-206306
Published: 2024
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Free
Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jayastu Senapati, Jan A. Burger, Gautam Borthakur, Mahesh Swaminathan, Koichi Takahashi, Zeev Estrov, Marina Y. Konopleva, Koji Sasaki, Tapan M. Kadia, Naveen Pemmaraju, Naval Daver, Elias Jabbour, Courtney D. DiNardo, Yesid Alvarado Valero, Musa Yilmaz, Prithviraj Bose, Maro Ohanian, Rashmi Kanagal-Shamanna, Keyur Patel, Jeffrey L. Jorgensen, Sa A. Wang, Sameh Nassar, Naveen Garg, Hyunsoo Hwang, Xuemei Wang, Nichole Cruz, Ana Ayala, William Plunkett, Hagop M. Kantarjian, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 4635.
https://doi.org/10.1182/blood-2023-189711
Published: 2023
Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Free
Nitin Jain, Philip Thompson, Akhil Jain, Jan A. Burger, Alessandra Ferrajoli, Jayastu Senapati, Koichi Takahashi, Mahesh Swaminathan, Zeev Estrov, Gautam Borthakur, Prithviraj Bose, Tapan M. Kadia, Naveen Pemmaraju, Koji Sasaki, Divyam Bansal, Marina Y. Konopleva, Elias Jabbour, Naveen Garg, Xuemei Wang, Rashmi Kanagal-Shamanna, Keyur P. Patel, Wei Wang, Sa A. Wang, Jeffrey L. Jorgensen, Wanda Lopez, Ana Ayala, William Plunkett, Varsha Gandhi, Hagop M. Kantarjian, Susan M. O'Brien, Michael J. Keating, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 3267.
https://doi.org/10.1182/blood-2023-188084
Published: 2023
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data

Free
Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jayastu Senapati, Jan A. Burger, Gautam Borthakur, Koichi Takahashi, Zeev E. Estrov, Marina Konopleva, Koji Sasaki, Tapan M. Kadia, Naveen Pemmaraju, Naval Daver, Elias Jabbour, Courtney D. DiNardo, Yesid Alvarado, Musa Yilmaz, Prithviraj Bose, Maro Ohanian, Rashmi Kanagal-Shamanna, Keyur Patel, Jeffrey L. Jorgensen, Sa A Wang, Sameh Nassar, Naveen Garg, Hyunsoo Hwang, Xuemei Wang, Nichole Cruz, Ana Ayala, William Plunkett, Hagop Kantarjian, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2022) 140 (Supplement 1): 234–237.
https://doi.org/10.1182/blood-2022-170850
Published: 2022
Journal Articles

Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year

Free
Philip A. Thompson, Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Christine B. Peterson, Naveen Garg, Ana Ayala, Jon A Hernandez, Tapan M. Kadia, Prithviraj Bose, Naveen Pemmaraju, Nicholas Short, William G. Wierda
Journal: Blood
Blood (2022) 140 (Supplement 1): 238–240.
https://doi.org/10.1182/blood-2022-170030
Published: 2022
Journal Articles

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Free
Nitin Jain, Alessandra Ferrajoli, Musa Yilmaz, Philip A. Thompson, Marina Konopleva, Michael R Green, Deepa Sampath, Sattva S. Neelapu, Koichi Takahashi, Lucia Masarova, Jan A. Burger, Rashmi Kanagal-Shamanna, Joseph D. Khoury, Naveen Garg, Xiaoping Su, Xuemei Wang, Hinalben Patel, Ana Ayala, Hagop Kantarjian, Michael J. Keating, William G. Wierda
Journal: Blood
Blood (2021) 138 (Supplement 1): 2626.
https://doi.org/10.1182/blood-2021-154195
Published: 2021
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results

Free
Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jan A. Burger, Gautam Borthakur, Koichi Takahashi, Zeev E. Estrov, Koji Sasaki, Tapan M. Kadia, Marina Konopleva, Yesid Alvarado, Musa Yilmaz, Courtney D. DiNardo, Prithviraj Bose, Maro Ohanian, Naveen Pemmaraju, Elias J. Jabbour, Rashmi Kanagal-Shamanna, Keyur Patel, Wei Wang, Jeffrey L. Jorgensen, Sa A Wang, Naveen Garg, Xuemei Wang, Chongjuan Wei, Nichole Cruz, Ana Ayala, William Plunkett, Hagop Kantarjian, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2021) 138 (Supplement 1): 3720.
https://doi.org/10.1182/blood-2021-154454
Published: 2021
Journal Articles

Venetoclax Consolidation in Patients with High-Risk CLL Who Have Been on Ibrutinib More Than a Year Achieves a High Rate of Undetectable Minimal Residual Disease

Free
Philip A. Thompson, Yan Wang, Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Christine B. Peterson, Naveen Garg, Chongjuan Wei, Ana Ayala, Tapan M. Kadia, Prithviraj Bose, Naveen Pemmaraju, Nicholas J. Short, William G. Wierda
Journal: Blood
Blood (2021) 138 (Supplement 1): 3723.
https://doi.org/10.1182/blood-2021-149919
Published: 2021
Journal Articles

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation

Free
Nitin Jain, Alessandra Ferrajoli, Philip A. Thompson, Marina Konopleva, Michael R Green, Deepa Sampath, Sattva S. Neelapu, Koichi Takahashi, Paolo Strati, Jan A. Burger, Rashmi Kanagal-Shamanna, Joseph D. Khoury, Naveen Garg, Xiaoping Su, Xuemei Wang, Hinalben Patel, Ana Ayala, Hagop Kantarjian, Michael J. Keating, William G. Wierda
Journal: Blood
Blood (2021) 138 (Supplement 1): 1550.
https://doi.org/10.1182/blood-2021-154279
Published: 2021
Journal Articles

The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL

Free
Philip A. Thompson, MB, MS, Alessandra Ferrajoli, MD, Nitin Jain, MD, Yan Wang, Christine B Peterson, Naveen Garg, MD, Chongjuan Wei, PhD, Ana Ayala, RN, Tapan M. Kadia, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Michael J. Keating, MBBS, William G. Wierda, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–29.
https://doi.org/10.1182/blood-2020-141716
Published: 2020
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results

Free
Nitin Jain, MD, Michael J. Keating, MBBS, Philip A. Thompson, MB, MS, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Gautam Borthakur, MD, Koichi Takahashi, MD PhD, Zeev E. Estrov, MD, Koji Sasaki, MD, Nathan H Fowler, MD, Tapan M. Kadia, MD, Marina Konopleva, MD PhD, Yesid Alvarado, MD, Musa Yilmaz, MD, Courtney D. DiNardo, MD MSCE, Prithviraj Bose, MD, Maro Ohanian, DO, Naveen Pemmaraju, MD, Elias Jabbour, MD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Wei Wang, MD PhD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Naveen Garg, MD, Xuemei Wang, MS, Chongjuan Wei, PhD, Nichole Cruz, RN, Ana Ayala, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD, Varsha Gandhi, PhD, William G. Wierda, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-142014
Published: 2020
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Free
Nitin Jain, MD, Michael J Keating, MBBS, Philip A. Thompson, MBBS, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Gautam M. Borthakur, MD, Koichi Takahashi, MD, Zeev E. Estrov, MD, Nathan H. Fowler, MD, Tapan M. Kadia, MD, Marina Y Konopleva, MD PhD, Yesid Alvarado, MD, Musa Yilmaz, MD, Courtney D. DiNardo, MDMSc, Prithviraj Bose, MD, Maro Ohanian, DO, Naveen Pemmaraju, MD, Elias Jabbour, MD, Koji Sasaki, MD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Naveen Garg, MD, Xuemei Wang, MS, Katrina Sondermann, BA, Nichole Cruz, RN, Chongjuan Wei, PhD, Ana Ayala, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD, Varsha Gandhi, PhD, William G. Wierda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 34.
https://doi.org/10.1182/blood-2019-131847
Published: 2019